天辰生物
Location: China, Pudong
Mentions in press and media 10
| Date | Title | Description |
| 25.11.2024 | Food Allergy: LongBio's LP-003 achieves its fourth IND approval | SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- LongBio is proud to announce that the National Medical Products Administration (NMPA, China) has approved the Investigational New Drug (IND) application for LP-003, the company's next-generation anti-... |
| 27.09.2024 | LongBio's Series B2 Financing: A Leap Towards Innovative Biologics | In the bustling world of biotechnology, where innovation is the lifeblood, LongBio Pharma (Suzhou) Co., Ltd. has made headlines with its recent Series B2 financing. The Shanghai-based company, which is deep into the Phase III stage of drug ... |
| 24.09.2024 | LongBio Closes Series B2 Financing | LongBio, a Shanghai, China-based Phase III-stage biotech company focused on the R&D of antibody and fusion protein drugs for allergies and complement-mediated diseases, raised an undisclosed amount in Series B2 funding. The round was le... |
| 24.09.2024 | LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners | SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio" or the "Company"), a Phase III-stage biotech company focused on the R&D of innovative antibody and fusion protein drugs for allerg... |
| 16.04.2024 | Pre-clinical result of LP-005, a novel bi-functional complement antibody-fusion protein was unveiled by LongBio at WCN2024 | BUENOS AIRES, Argentina, April 16, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. (referred to as "LongBio"), a leading biotech company dedicated to developing innovative protein treatments for nephrology, allergy, respira... |
| 12.03.2024 | Longbio Pharma Presented Positive Phase 1 Results for LP-003 at 2024AAD | SAN DIEGO, March 12, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, ... |
| 26.02.2024 | Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024 | WASHINGTON, Feb. 26, 2024 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio Pharma"), a leading biotech company dedicated to developing innovative protein treatments for allergy, respiratory, dermatology, ... |
| 23.10.2023 | Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at JSA2023 | TOKYO, Oct. 23, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a biotech company specializing in the development of treatments for allergy, asthma, nephrology, dermatology, ophthalmology ... |
| 20.06.2023 | Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023 | SOFIA, Bulgaria, June 20, 2023 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (abbreviated as "Longbio Pharma"), a pharmaceutical company that develops medicines for the treatment of allergy, asthma, ophthalmology and other aut... |
| - | LongBio Pharma | “Longbio Pharma” |